Eli Lilly and Company has taken the lead in in the production of tirzepatide, a groundbreaking drug for type 2 diabetes. Tirzepatide, a dual GIP and GLP-1 receptor agonist, showcases significant potential to improve glycemic control and reduce cardiovascular risks. The sophisticated synthesis of tirzepatide involves a series of meticulous processes